Autolus Therapeutics
AUTL
71 hedge funds and large institutions have $204M invested in Autolus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 15 closing their positions.
11,033% more call options, than puts
Call options by funds: $334K | Put options by funds: $3K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
93% more capital invested
Capital invested by funds: $106M → $204M (+$98.5M)
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
10.39% more ownership
Funds ownership: 54.3% → 64.69% (+10%)
8% more funds holding
Funds holding: 66 → 71 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$37.9M |
| 2 |
SP
Syncona Portfolio
St Peter Port,
Guernsey
|
+$35.4M |
| 3 |
AC
Armistice Capital
New York
|
+$25.9M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$13.3M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.25M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$961K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$916K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$214K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$202K |
AUTL Hedge Fund Activity: Q4 2022 in Review
71 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2022, worth a combined $204M — up 93% from $106M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new AUTL positions and 15 closed out — a net gain of 6 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $37.9M. The largest seller was UBS O'Connor, exiting entirely with an estimated $1.25M sold.
- 71 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2022, up from 66 in Q3 2022.
- Funds reported $204M of Autolus Therapeutics stock for Q4 2022, up 93% quarter-over-quarter.
- 21 funds opened new Autolus Therapeutics positions in Q4 2022 and 15 closed out, a net change of +6 holders.
- The largest Autolus Therapeutics buyer in Q4 2022 was Deep Track Capital, an estimated $37.9M added.
- The largest Autolus Therapeutics seller in Q4 2022 was UBS O'Connor, an estimated $1.25M sold.
Based on aggregated 13F filings for Q4 2022.